Drug Details

General Information of the Drug (ID: DR4671)
Name
Zafirlukast
Synonyms
zafirlukast; 107753-78-6; Accolate; Olmoran; ICI-204219; Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate; Accoleit; ICI 204219; ICI 204,219; C31H33N3O6S; UNII-XZ629S5L50; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Zafirlukast (Accolate); CHEMBL603; Aeronix; CHEBI:10100; XZ629S5L50; MFCD00864775; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; NCGC00164547-01; NCGC00164547-06; Vanticon; DSSTox_CID_3746; DSSTox_RID_77181; DSSTox_GSID_23746; cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Zafirst; Respix; Accolate (TN); Cyclopentyl 3-{2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl}-1-methyl-1H-indol-5-ylcarbamate; cyclopentyl N-{3-[(2-methoxy-4-{[(2-methylbenzene)sulfonyl]carbamoyl}phenyl)methyl]-1-methyl-1H-indol-5-yl}carbamate; N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic Acid Cyclopentyl Ester; SMR000466316; CAS-107753-78-6; SR-01000759386; Zafirlucast; Zafirlukast (JAN/USAN/INN); Zafirlukast [USAN:INN:BAN]; Zafirlukast(Accolate); PubChem18223; CPD000466316; ACMC-209wlw; cc-92; SCHEMBL4175; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; MLS000759421; MLS001424064; MLS006011771; BIDD:GT0267; GTPL3322; DTXSID5023746; Zafirlukast, >=98% (HPLC); HMS2051F12; HMS2089J10; HMS3393F12; HMS3650A04; HMS3655E13; HMS3713J08; HMS3745K03; ZINC896717; BCP05226; Tox21_112176; ANW-46530; BDBM50009073; s1633; STK646780; AKOS005577888; Tox21_112176_1; AC-9018; CCG-101025; DB00549; MCULE-2053856450; NC00275; SB19079; NCGC00164547-02; NCGC00164547-03; NCGC00164547-04; NCGC00164547-05; AS-12943; cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; cyclopentyl N-[3-[[2-methoxy-4-(o-tolylsulfonylcarbamoyl)phenyl]methyl]-1-methyl-indol-5-yl]carbamate; HY-17492; AB0012638; FT-0601575; MLS000759421-02; SW197655-3; C07206; D00411; 32256-EP2270008A1; 32256-EP2280006A1; 32256-EP2281813A1; 32256-EP2281815A1; 32256-EP2281819A1; 32256-EP2284166A1; 32256-EP2292617A1; 32256-EP2292619A1; 32256-EP2295409A1; 32256-EP2298415A1; 32256-EP2301933A1; 32256-EP2305640A2; 32256-EP2305659A1; 32256-EP2308562A2; 32256-EP2311818A1; 32256-EP2311827A1; AB00639922-06; AB00639922-08; AB00639922_09; 753Z786; A801752; L001011; Q928378; Q-201940; SR-01000759386-4; SR-01000759386-5; SR-01000759386-9; BRD-K71289571-001-06-4; Z1551429730; Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)-carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate; cyclopentyl 3-(2-methoxy-4-(o-tolylsulfonylcarbamoyl)benzyl)-1-methyl-1H-indol-5-ylcarbamate; cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methyl-1H-indol-5-yl]carbamate; cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-indol-5-yl]carbamate; Cyclopentyl N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamate; N-[3-[[2-methoxy-4-[[(2-methylphenyl)sulfonylamino]-oxomethyl]phenyl]methyl]-1-methyl-5-indolyl]carbamic acid cyclopentyl ester; ZLK
    Click to Show/Hide
Molecular Type
Small molecule
Disease Asthma [ICD-11: CA23] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Clearance
The apparent oral clearance of drug is 20 L/h
Elimination
0% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 10 hours
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.9926 micromolar/kg/day
Vd
The volume of distribution (Vd) of drug is 70 L
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C31H33N3O6S
PubChem CID
5717
Canonical SMILES
CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
InChI
1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
InChIKey
YEEZWCHGZNKEEK-UHFFFAOYSA-N
CAS Number
CAS 107753-78-6
ChEBI ID
CHEBI:10100
TTD Drug ID
D05DVP
DrugBank ID
DB00549
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug
          Vincamine      Vinca minor     Click to Show/Hide the Molecular Data of This NP
                 Decreasing Adverse Drug Reaction     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression CASP3  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation ERK1  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation JNK1  Molecule Info 
Pathway MAP
Down-regulation Expression p105  Molecule Info 
Pathway MAP
                    In-vivo Model Adult female Wistar albino rats were used in this study.
                    Experimental
                    Result(s)		 Zafirlukast and vincamine may be regarded as potential therapeutic strategies with antioxidant and anti-inflammatory activities against tamoxifen-induced oxidative damage in rat liver.
Target and Pathway
Target(s) Leukotriene CysLT1 receptor (CYSLTR1)  Molecule Info  [3]
KEGG Pathway Calcium signaling pathway Click to Show/Hide
2 Neuroactive ligand-receptor interaction
NetPath Pathway TGF_beta_Receptor Signaling Pathway Click to Show/Hide
2 IL4 Signaling Pathway
3 IL3 Signaling Pathway
Pathway Interaction Database Endothelins Click to Show/Hide
Reactome Leukotriene receptors Click to Show/Hide
2 G alpha (q) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like Click to Show/Hide
2 Gastrin-CREB signalling pathway via PKC and MAPK
3 GPCR ligand binding
4 GPCR downstream signaling
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3322).
Reference 2 Zafirlukast and vincamine ameliorate tamoxifen-induced oxidative stress and inflammation: Role of the JNK/ERK pathway. Life Sci. 2018 Jun 1;202:78-88.
Reference 3 Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link